Personal information

Verified email domains

United Kingdom

Biography

Dr Morgan completed his BSc in Biomedical Science at the University of Portsmouth (2004-2007) before completing a PhD in leukaemia research at Cardiff University (2007-2011) in the world leading Haematology department headed by Professor Alan Burnett. His thesis examined the role of a Wnt signalling protein (gamma-catenin) in acute myeloid leukaemia (AML) under the supervision of Professors Alex Tonks and Richard Darley.

From here Rhys joined the School of Cellular & Molecular Medicine at the University of Bristol in 2013 to pursue his interests in signal transduction and cancer biology. Under the supervision of Professors Christos Paraskeva and Ann Williams he undertook post-doctoral studies investigating the role of the stem cell marker LGR5 and Wnt/EGF signal transduction in colorectal cancer.

In 2016, whilst at the University of Bristol, Rhys was awarded a prestigious Kay Kendall Leukaemia Fund (KKLF) Junior Fellowship to examine the Wnt/beta-catenin signalling in AML. In 2018 Dr Morgan joined the Department of Biochemistry and Biomedicine at the School of Life Sciences, University of Sussex to establish his own leukaemia research group.

From July 2019 he assumed the role of Lecturer in Biomedical Science and continues his research interests in cell signalling and leukaemia. Dr Morgan is now Director of the Haematology Research Group, a group he established in 2019 to bring together researchers from the School of Life Sciences and Brighton and Sussex Medical School with shared haematological research interests. Rhys was promoted to Associate Professor of Cancer Biology in October 2022.

Activities

Employment (6)

University of Sussex: Brighton, GB

Employment
Source: check_circle
University of Sussex - Elements

University of Sussex: Brighton, Brighton and Hove, GB

2018-05-01 to present | Kay Kendall Leukaemia Fund (KKLF) Junior Fellow (School of Life Sciences)
Employment
Source: Self-asserted source
Rhys Morgan

University of Bristol: Bristol, GB

2019-03-31
Employment
Source: check_circle
University of Bristol - PURE

University of Bristol: Bristol, Bristol, GB

2016-07-01 to 2018-04-30 | Kay Kendall Leukaemia Fund (KKLF) Junior Fellow (School of Cellular & Molecular Medicine)
Employment
Source: Self-asserted source
Rhys Morgan

University of Bristol: Bristol, Bristol, GB

2013-01-01 to 2016-06-31 | Research Associate (Cellular & Molecular Medicine)
Employment
Source: Self-asserted source
Rhys Morgan

Cardiff University School of Medicine: Cardiff, Cardiff, GB

2010-01-11 to 2012-12-31 | Research Assistant (Haematology)
Employment
Source: Self-asserted source
Rhys Morgan

Education and qualifications (2)

Cardiff University School of Medicine: Cardiff, Cardiff, GB

2007-10-01 to 2011-05-01 | Doctor of Philosophy (PhD)
Education
Source: Self-asserted source
Rhys Morgan

University of Portsmouth: Portsmouth, Hampshire, GB

2004-10-01 to 2007-07-01 | Biomedical Science
Education
Source: Self-asserted source
Rhys Morgan

Professional activities (4)

Leukaemia & Myeloma Research UK: Liverpool, Merseyside, GB

2020-01-01 to present | Research Review Committee Member
Invited position
Source: Self-asserted source
Rhys Morgan

Sussex Haematology Research Group: Brighton, Sussex, GB

2019-01-01 to present | Director
Membership
Source: Self-asserted source
Rhys Morgan

American Society of Hematology: Washington, DC, US

2016-06-24 to present | International Associate Member
Membership
Source: Self-asserted source
Rhys Morgan

British Society for Haematology: London, London, GB

2015-05-01 to present | Full member (reduced)
Membership
Source: Self-asserted source
Rhys Morgan

Funding (6)

Interrogating the Wnt signalling-responsive surfaceome for drug targets in acute myeloid leukaemia (AML)

2022-03 to 2025-03 | Grant
Kay Kendall Leukaemia Fund (London, GB)
GRANT_NUMBER:

KKL1446

Source: Self-asserted source
Rhys Morgan

Targeting beta-catenin:RNA protein interactions in acute myeloid leukaemia (AML)

2021-06 to 2022-04 | Grant
Leukaemia and Myeloma Research UK (Liverpool, GB)
Source: Self-asserted source
Rhys Morgan

Mining the Wnt signalling-responsive surfaceome for drug targets in acute myeloid leukaemia (AML)

2020-07 to 2021-12 | Grant
Wellcome Trust (London, GB)
Source: Self-asserted source
Rhys Morgan

Characterizing the ß-Catenin Interactome in Childhood Mixed-Lineage Leukaemia Rearranged Acute Myeloid Leukaemia (MLL-AML)

2018-08 to 2019-08 | Grant
The Royal Society (London, GB)
GRANT_NUMBER:

RG160682

Source: Self-asserted source
Rhys Morgan

Characterising the β-catenin interactome in primary acute myeloid leukaemia blasts

2017-02 to 2018-02 | Grant
British Society for Haematology (London, GB)
GRANT_NUMBER:

34725/startup

Source: Self-asserted source
Rhys Morgan

Targeting nuclear β-catenin in acute leukaemia

2016-07 to 2019-07 | Grant
Kay Kendall Leukaemia Fund (London, GB)
GRANT_NUMBER:

KKL1051

Source: Self-asserted source
Rhys Morgan

Peer review (7 reviews for 4 publications/grants)

Review activity for Cancer gene therapy. (3)
Review activity for Communications biology. (1)
Review activity for Oncogene. (1)
Review activity for UK Research and Innovation (2)